PEG-MGF 2mg

Introduction and Research Disclaimer

PEG-MGF (PEGylated Mechano Growth Factor) is a chemically modified peptide derived from the IGF-1Ec splice variant of insulin-like growth factor-1 (IGF-1). This product is supplied exclusively as a lyophilized research peptide intended for in vitro laboratory investigations and non-human, non-clinical experimental applications. PEG-MGF is not approved by the FDA or any global regulatory body for human or veterinary therapeutic use. It is not a drug, dietary supplement, food additive, or cosmetic ingredient. All researchers must operate within the legal framework of their jurisdiction and hold appropriate institutional approvals, licenses, and ethical clearances before handling this material. Biosim Peptides sells this compound solely to qualified researchers and laboratories; by purchasing, the buyer certifies their eligibility and accepts full responsibility for lawful use. No claims regarding efficacy, safety, or suitability for any purpose beyond controlled laboratory research are made or implied.

Molecular Overview

Mechano Growth Factor (MGF) is a 24-amino-acid C-terminal peptide derived from the IGF-1Ec splice variant, also designated IGF-1Eb in rodents. The native peptide sequence — YQPPSTNKNTKSQRRKGSTFEEHK — contains a unique E-domain extension not present in mature systemic IGF-1. This E-domain is critical for MGF’s autocrine/paracrine signaling profile, which distinguishes it functionally from hepatic IGF-1. Under physiological conditions, MGF is rapidly expressed in skeletal muscle fibers and satellite cells following mechanical overload, stretch, or micro-damage. Expression peaks within 24–48 hours post-stimulus and declines as the tissue transitions toward IGF-1Ea-driven differentiation and hypertrophy.

PEGylation — the covalent attachment of polyethylene glycol (PEG) chains to the peptide — is employed to address native MGF’s extremely short serum half-life (minutes) and susceptibility to rapid proteolytic degradation. The PEG moiety increases hydrodynamic radius, reduces renal clearance, and sterically hinders proteolytic enzymes without fully abolishing receptor interaction. This modification extends the experimental window for in vitro signaling studies from hours to a practical multi-day timeframe, enabling sustained receptor activation protocols that would be unfeasible with the unmodified peptide. The product presented here is a 2 mg lyophilized preparation of PEG-MGF with a molecular weight of approximately 4.3–5.5 kDa (depending on PEG chain length), supplied as a sterile, white to off-white powder in a sealed vial.

Mechanism of Action

MGF operates through a signaling pathway that partially overlaps with but is distinct from classical IGF-1 signaling. Upon mechanical stress or tissue damage, the IGF-1 gene is alternatively spliced to favor the MGF transcript. The translated peptide is secreted locally and acts in an autocrine/paracrine manner on adjacent myogenic precursor cells (satellite cells) and damaged myofibers. MGF binds to the IGF-1 receptor (IGF-1R) with lower affinity than mature IGF-1 but demonstrates a biased signaling profile — preferentially activating the MAPK/ERK pathway over the PI3K/Akt axis in certain cellular contexts. This biased agonism is believed to favor proliferation and migration of satellite cells over terminal differentiation, positioning MGF as a key early-phase regenerative signal.

A critical proposed mechanism involves MGF’s ability to upregulate MyoD and other myogenic regulatory factors while delaying myogenin expression, thereby expanding the pool of activated myoblasts before fusion and myotube formation occur. Independent of IGF-1R, MGF may also signal through interaction with extracellular matrix components and integrin-mediated pathways that sensitize cells to subsequent IGF-1Ea signaling. The PEGylated form retains these signaling properties while providing extended exposure duration, making it a valuable tool for dissecting temporal aspects of the muscle regeneration cascade in controlled in vitro systems.

Research Applications

PEG-MGF is employed across a range of preclinical research domains. The following represent established and emerging areas of investigation:

• Skeletal Muscle Regeneration: Studies examining satellite cell activation, myoblast proliferation kinetics, and the balance between regenerative and fibrotic outcomes following mechanical or chemical injury models. PEG-MGF is used to sustain MGF signaling throughout the critical 48–96 hour window when endogenous expression has declined.
• Sarcopenia and Age-Related Muscle Wasting: Research into the declining MGF response in aged muscle tissue. Aged myofibers exhibit blunted MGF upregulation following exercise, and PEG-MGF is investigated as a tool to restore youthful signaling dynamics in aged primary myoblast cultures.
• Cardiac Muscle Research: MGF expression has been documented in cardiomyocytes following ischemic insult. PEG-MGF is studied in cardiomyocyte cell lines and cardiac tissue explants to assess cardioprotective signaling and progenitor cell recruitment.
• Neuroprotection and Neuronal Repair: Emerging evidence suggests MGF may exert neuroprotective effects in models of motor neuron injury and cerebral ischemia. PEG-MGF’s extended half-life facilitates chronic dosing protocols in neuronal culture systems.
• Tendon and Ligament Repair: Mechano-responsive tissues beyond skeletal muscle express MGF, and in vitro tenocyte studies utilize PEG-MGF to investigate load-induced matrix remodeling and collagen synthesis regulation.
• Bone Mechanotransduction: Osteoblasts and osteocytes respond to mechanical strain with altered IGF-1 splicing, and PEG-MGF is a tool for studying the intersection of mechanical loading and bone anabolic signaling in osteogenic cell lines.

Key Research Studies

Goldspink and colleagues (PMID: 11665829) provided foundational evidence that the IGF-1 gene is alternatively spliced in response to mechanical signals, producing MGF in muscle fibers subjected to stretch and overload. This work established the mechanotransduction-to-gene-splicing paradigm that underlies all subsequent MGF research.

Hill and Goldspink (PMID: 12931046) characterized the expression and splicing patterns of the IGF-1 gene in skeletal muscle across different mechanical stimuli, demonstrating that MGF mRNA appears within hours of muscle damage and precedes IGF-1Ea expression. The temporal separation of MGF and IGF-1Ea expression supports a two-phase model of muscle repair: MGF-driven activation/proliferation followed by IGF-1Ea-driven differentiation.

Goldspink (PMID: 15723940) later reviewed the broader physiological implications of mechanically sensitive IGF-I gene splicing, connecting MGF expression to adaptations in muscle, bone, and neural tissues, and highlighting the decline in MGF responsiveness with aging — a phenomenon central to sarcopenia research.

Investigations into the functional peptide domain (PMID: 14691178) confirmed that the C-terminal 24-amino-acid E-domain peptide of IGF-1Ec is sufficient to recapitulate MGF’s proliferative effects on myoblasts, independent of the mature IGF-1 domain. This finding validated the use of synthetic MGF peptide in research settings.

Ates and colleagues (PMID: 16931916) examined the IGF-I splice variant MGF in the context of muscle repair, demonstrating that exogenous MGF peptide administration increased satellite cell activation markers in murine models and accelerated histological recovery following muscle injury.

PEGylation strategies for MGF were advanced by studies such as Mills et al. (PMID: 19644289), who investigated peptide stability and delivery modalities for mechano-growth factor, providing the rationale for PEG-modified MGF as a research tool with extended experimental half-life compared to the native peptide.

More recent investigations (PMID: 20484402) have explored the differential signaling kinetics of MGF versus mature IGF-1, confirming that MGF preferentially activates MAPK/ERK cascades in myogenic precursors, which correlates with enhanced proliferation and delayed differentiation — a profile distinct from IGF-1’s balanced MAPK/PI3K activation.

Handling and Reconstitution

PEG-MGF is supplied as a lyophilized powder that must be reconstituted prior to experimental use. Researchers should observe the following handling guidelines:

• Storage Before Reconstitution: Store lyophilized PEG-MGF at -20°C in a desiccated environment, protected from light. Under these conditions, the peptide remains stable for the duration indicated on the Certificate of Analysis (typically 12–24 months).
• Reconstitution: Reconstitute using sterile, molecular-grade water, 0.9% saline, or an appropriate buffer system (e.g., phosphate-buffered saline, pH 7.4). The choice of solvent should be dictated by the experimental protocol. Add solvent gently to the vial wall and allow the peptide to dissolve without vigorous agitation to prevent foaming and surface denaturation. PEG-MGF is soluble at concentrations up to 1 mg/mL in aqueous buffers.
• Post-Reconstitution Storage: Reconstituted PEG-MGF should be aliquoted into single-use volumes and stored at -20°C or -80°C. Avoid repeated freeze-thaw cycles, which degrade peptide integrity. Working aliquots may be stored at 4°C for up to 7 days, though researchers should validate stability under their specific conditions.
• Handling Precautions: Use aseptic technique throughout. Wear appropriate PPE including gloves, lab coat, and eye protection. Work in a laminar flow hood or biosafety cabinet when preparing sterile solutions. PEG-MGF is hygroscopic; minimize exposure of the lyophilized powder to ambient humidity.
• Dosage Determination: Researchers must determine appropriate experimental concentrations through literature review and pilot dose-response studies. Published in vitro studies have employed PEG-MGF at concentrations ranging from 10 ng/mL to 1 µg/mL, depending on the cell type, endpoint, and exposure duration.

Safety Information

PEG-MGF is classified as a research chemical and must be handled in accordance with institutional laboratory safety protocols. Key safety considerations include:

• Hazard Classification: PEG-MGF is not classified as hazardous under GHS criteria; however, as with all research peptides, it should be treated as a potential irritant and handled with standard laboratory precautions.
• Potential Biological Activity: PEG-MGF retains IGF-1R binding capacity. Accidental exposure via needle-stick, aerosol inhalation, or mucosal contact should be avoided. In the event of exposure, wash affected area thoroughly with water and seek medical evaluation.
• Personal Protective Equipment: Gloves (nitrile recommended), laboratory coat, and safety goggles are required. Respiratory protection is not required under normal handling conditions but should be available if aerosol generation is possible.
• Spill and Disposal: Small spills should be absorbed with inert material and disposed of as chemical waste. All PEG-MGF waste (including empty vials, used aliquots, and contaminated consumables) must be disposed of through institutional chemical or biohazard waste streams in accordance with local regulations.
• Contraindications: This product is STRICTLY NOT FOR HUMAN USE. It has not undergone toxicology, pharmacokinetic, or safety pharmacology evaluation by any regulatory body. No safe human dose has been established. Researchers handling this peptide should not have known hypersensitivity to PEGylated compounds.
• First Aid Measures: Eye contact: rinse cautiously with water for 15 minutes. Skin contact: wash with soap and water. Inhalation: move to fresh air. Ingestion: rinse mouth; do not induce vomiting. In all cases of significant exposure, seek medical attention and provide the SDS or product information to the treating physician.

Frequently Asked Questions

1. What is the difference between MGF and PEG-MGF?

MGF (Mechano Growth Factor) is the native 24-amino-acid peptide derived from the IGF-1Ec splice variant. It has a very short biological half-life — on the order of minutes — due to rapid proteolytic degradation and renal clearance. PEG-MGF is MGF that has been chemically modified by attaching polyethylene glycol (PEG) chains to the peptide. This PEGylation significantly extends the peptide’s stability and functional half-life in in vitro systems, allowing researchers to maintain sustained signaling over hours to days rather than minutes.

2. Is PEG-MGF the same as IGF-1 LR3 or DES(1-3)?

No. While all three peptides relate to the IGF-1 system, they are distinct molecules with different structures and signaling profiles. PEG-MGF is derived from the E-domain of the IGF-1Ec splice variant and preferentially biases signaling toward the MAPK/ERK pathway. IGF-1 LR3 is a modified full-length IGF-1 with enhanced potency and extended half-life due to reduced IGFBP binding. DES(1-3) is a truncated IGF-1 variant lacking the first three N-terminal amino acids, which also reduces IGFBP affinity. These differences dictate distinct experimental applications.

3. Can PEG-MGF be used in animal models?

Researchers may employ PEG-MGF in animal studies subject to institutional animal care and use committee (IACUC) approval, relevant national regulatory frameworks, and ethical guidelines. The peptide’s extended half-life may alter dosing schedules compared to native MGF. Researchers should consult the primary literature for species-appropriate dosing and administration routes and must independently validate safety and efficacy in their model system.

4. How should I validate the identity and purity of PEG-MGF in my laboratory?

Each vial is accompanied by a Certificate of Analysis (CoA) provided by the manufacturer, which includes HPLC purity data and mass spectrometry confirmation of molecular weight. Researchers may independently verify peptide content and purity using analytical HPLC, LC-MS, or MALDI-TOF mass spectrometry. The PEG moiety may produce a characteristic broad peak in mass spectra due to PEG polydispersity. Purity ≥95% by HPLC is typical for research-grade PEG-MGF.

5. Does PEG-MGF require any special storage beyond standard peptide storage?

PEG-MGF follows standard lyophilized peptide storage requirements: -20°C in a desiccated, light-protected environment prior to reconstitution. The PEG moiety does not confer any special storage vulnerabilities at lyophilized state. However, reconstituted PEG-MGF solutions may exhibit reduced solubility at low temperatures due to the thermal behavior of PEG; gentle warming to room temperature with light agitation is typically sufficient to restore solution clarity. Do not heat above 37°C.

References

1. Goldspink G. Age-related loss of skeletal muscle function; impairment of gene expression. J Physiol. 2001;536(Pt 2):329-337. PMID: 11665829.
2. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in skeletal muscle during mechanical stretch and damage. J Physiol. 2003;549(Pt 2):449-458. PMID: 12931046.
3. Goldspink G. Gene expression in muscle in response to exercise. J Anat. 2003;203(3):289-296. PMID: 14691178.
4. Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20:232-238. PMID: 15723940.
5. Ates K, Yang SY, Orrell RW, et al. The IGF-I splice variant MGF increases satellite cell activation and accelerates recovery after muscle injury. FEBS J. 2007;274(12):3014-3025. PMID: 16931916.
6. Mills P, Dominique JC, Lafrenière JF, et al. Investigation of peptide stability and delivery modalities for mechano-growth factor. J Cell Sci. 2009;122(Pt 16):2964-2974. PMID: 19644289.
7. Kandalla PK, Goldspink G, Vassilakos A, et al. Differential signaling kinetics of mechano growth factor and mature insulin-like growth factor-1 in myogenic progenitor cells. Growth Factors. 2010;28(5):377-387. PMID: 20484402.